EVERSENSE, Accu-Chek (Roche)
The Eversense system continually measures interstitial fluid glucose levels in adults with
diabetes for the operating life of the sensor, which is 180 days (six months). Although the
CGM is implanted the user wears a reader on the skin above the technology, including
glucose trend information and includes alarms for the detection and prediction of
episodes of hypo and hyper. This data can be transmitted via an app to a smartphone.
The aim is that the system will allow users to manage their diabetes with more flexibility,
confidence and discretion. The system needs calibrating twice a day with a blood
glucose reading. The Eversense sensor
is inserted in a clinical environment, the
implanted sensor is powered wirelessly by
the transmitter placed on the arm directly
over the sensor. There are a few centres
where implants can be done. Contact
Accu-Chek direct or talk to the people at
London Diabetes Centre.